Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.

"Declarations Ethics approval and consent to participateAll of the human post-mortem materials used in this study were obtained from subjects who had been evaluated at the Sunnybrook Health Sciences Centre ALS Clinic and the University of British Columbia Clinic for Alzheimer’s Disease and Related Disorders, and consented for research purposes in accordance with respective ethical review boards. Consent for publicationNot applicable. Competing interestsN.R.C., J.M.K., and B.Z. are current employees of ProMIS Neurosciences. S.S.P. and S.C.C.H. have received consultation compensation from ProMIS Neurosciences. S.S.P. and B.Z. possess ProMIS stock options. N.R.C. and J.M.K. possess ProMIS shares and stock options. S.S.P. is the inventor on patent applications for Collective Coordinates computational modeling. N.R.C., S.S.P., J.M.K., and B.Z. are inventors on patent applications relating to conformation-specific epitopes in RACK1, antibodies thereto and methods related thereof. Competing interests N.R.C., J.M.K., and B.Z. are current employees of ProMIS Neurosciences. S.S.P. and S.C.C.H. have received consultation compensation from ProMIS Neurosciences. S.S.P. and B.Z. possess ProMIS stock options. N.R.C. and J.M.K. possess ProMIS shares and stock options. S.S.P. is the inventor on patent applications for Collective Coordinates computational modeling. N.R.C., S.S.P., J.M.K., and B.Z. are inventors on patent applications relating to conformation-specific epitopes in RACK1, antibodies thereto and methods related thereof."

"Funding This work was sponsored by Canadian Institute of Health Research (PJT-159546 and CIHR-CCNA grant 20R04367), Brain Canada (20R74974), ALS Canada/Brain Canada 2020 Discovery Grant Program (F20-04056), William A. Lambert donation (F17-00928), and ProMIS Neurosciences (SRA F16-05805)."